1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ReNeuron Outlines First-To-Market Plans For Stroke Disability Cell Therapy

 
• By Lucie Ellis-Taitt

ReNeuron has high hopes of being the first to reach the US market with a novel stem cell therapy for use in patients with disabilities caused by stroke – CEO Olav Hellebø outlines the company's plans for Phase III and eventual commercialization.

Brain concept
• Source: Shutterstock

ReNeuron Group PLC is planning "world domination" for stem cell therapy use in ischemic stroke, says CEO Olav Hellebø; the UK biotech wants to commercialize its potential blockbuster therapy alone in the US and Europe, but seek a local partner to help conquer the market in Japan.

ReNeuron's lead compound, CTX (ReN001), is being developed as a cell therapy treatment to reverse the functional deficits associated with stroke disability. The company expects to launch a pivotal Phase III trial in the first half of 2018, once it has secured a Regenerative Medicine Advanced Therapy (RMAT) designation for the product in the US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

More from R&D

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.